FDA Grants Priority Review for BIZENGRI Supplement by Merus N.V.
The FDA has granted priority review for the supplemental application of BIZENGRI (ZENOCUTUZUMAB-ZBCO) submitted by Merus N.V.
Asset / Drug
Drug and asset intelligence for BIZENGRI with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
July 14, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.